“The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator initiative has announced a new $5 million commitment to projects targeting the development of biomarkers for frontotemporal degeneration (FTD), the most common dementia for people under 60. A new $2.5 million research investment from The Association for Frontotemporal Degeneration (AFTD) is being matched by a $2.5 million allocation of the ADDF’s Diagnostics Accelerator funds.”
Read the full story at prnewswire.com
The Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Initiative Expands Its Focus on Frontotemporal Degeneration | PR Newswire
More from Current EventMore posts in Current Event »
- Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta | Med City News
- Former NFL Wife on Her Husband’s Battle with CTE
- Capito, Collins introduce bill to increase awareness of Alzheimer’s services | Ripon Advance
- ‘Young Blood’ Researchers Are Still in the Pursuit to Stall Aging, Slow Alzheimer’s | Being Patient
- ‘It is not alarmist to say that the people of Florida are being slowly poisoned by the water’ | Opinion | Miami Herald